Edition:
United Kingdom

MediciNova Inc (MNOV.OQ)

MNOV.OQ on NASDAQ Stock Exchange Global Market

11.20USD
20 Apr 2018
Change (% chg)

$-0.36 (-3.11%)
Prev Close
$11.56
Open
$11.57
Day's High
$11.85
Day's Low
$11.19
Volume
75,787
Avg. Vol
81,847
52-wk High
$14.50
52-wk Low
$4.40

Latest Key Developments (Source: Significant Developments)

MediciNova Posts Results Of Phase 2 Clinical Trial Of MN-166 In Methamphetamine Dependence
Thursday, 29 Mar 2018 

March 29 (Reuters) - MediciNova Inc ::MEDICINOVA ANNOUNCES RESULTS OF PHASE 2 CLINICAL TRIAL OF MN-166 (IBUDILAST) IN METHAMPHETAMINE DEPENDENCE.MEDICINOVA INC - ‍DID NOT MEET PRIMARY ENDPOINT OF METHAMPHETAMINE ABSTINENCE CONFIRMED VIA URINE DRUG SCREENS DURING FINAL TWO WEEKS OF TREATMENT​.MEDICINOVA INC - ‍MN-166 (IBUDILAST) DEMONSTRATED A FAVORABLE SAFETY AND TOLERABILITY PROFILE​.MEDICINOVA INC - ‍THERE WAS NOT AN INCREASED RATE OF SERIOUS OR SEVERE ADVERSE EVENTS IN MN-166 (IBUDILAST) GROUP COMPARED TO PLACEBO GROUP​.MEDICINOVA INC SAYS THERE WERE NO INFECTIONS, NO CANCERS, NO CARDIOVASCULAR EVENTS NO DEATHS RELATED TO MN-166.MEDICINOVA - COMMON TREATMENT-RELATED ADVERSE EVENTS DURING STUDY WERE GASTROINTESTINAL ADVERSE EVENTS, OCCURRED WITH HIGHER FREQUENCY IN MN-166 GROUP​.  Full Article

Medicinova Announces Positive Top-Line Results From Clinical Trial Of MN-166 (ibudilast) In ALS
Thursday, 7 Dec 2017 

Dec 7 (Reuters) - Medicinova Inc ::MEDICINOVA ANNOUNCES POSITIVE TOP-LINE RESULTS FROM THE CLINICAL TRIAL OF MN-166 (IBUDILAST) IN ALS.MEDICINOVA INC - TRIAL ACHIEVED PRIMARY ENDPOINT OF SAFETY AND TOLERABILITY, AND ALSO DEMONSTRATED EFFICACY TRENDS IN FAVOR OF MN-166.MEDICINOVA INC - THERE WERE 7 SERIOUS ADVERSE EVENTS (SAES) REPORTED DURING STUDY BUT NONE OF SAES WERE RELATED TO STUDY DRUG.MEDICINOVA INC - MN-166 DEMONSTRATED A FAVORABLE SAFETY AND TOLERABILITY PROFILE. ALL SUBJECTS IN STUDY RECEIVED 100 MG OF RILUZOLE PER DAY.MEDICINOVA INC - ALL TREATMENT-RELATED ADVERSE EVENTS (TRAES) WERE MILD TO MODERATE IN INTENSITY & NO SEVERE OR LIFE-THREATENING TRAES WERE REPORTED.  Full Article

Medicinova announces positive top-line results from the Sprint-MS Phase 2B trial of MN-166 (ibudilast)
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - Medicinova Inc ::Medicinova announces positive top-line results from the Sprint-MS phase 2B trial of MN-166 (ibudilast) in progressive MS: achieved both primary endpoints including a significant reduction in whole brain atrophy and safety and tolerability.Medicinova Inc - ‍MN-166 demonstrated a statistically significant reduction in rate of progression of whole brain atrophy compared to placebo in study​.Medicinova Inc - ‍MN-166 was safe and well tolerated in study​.  Full Article

MediciNova sees loss per share for year ending Dec 31 of $0.31
Wednesday, 27 Jul 2016 

MediciNova Inc : Says expected loss per share for year ending December 31, 2016 is $0.31 .FY 2016 earnings per share view $-0.31 -- Thomson Reuters I/B/E/S.  Full Article

MediciNova receives notice of allowance for new patent covering MN-001 and MN-002 for the treatment of fibrosis
Tuesday, 26 Jul 2016 

MediciNova Inc :Says it received a notice of allowance from the U.S. Patent And Trademark Office (Uspto) for a pending patent application which covers Mn-001 (Tipelukast) and Mn-002 (A Major Metabolite Of Mn-001) for the treatment of “Fibrosis” which includes a broad range of fibrosis / fibrotic disease in different organs due to different causes.  Full Article

Medicinova receives notice of allowance for new patent covering MN-001 and MN-002 for treatment of Fibrosis
Monday, 25 Jul 2016 

Medicinova : Receives notice of allowance for new patent covering MN-001 and MN-002 for treatment of Fibrosis .Says once issued, patent maturing from this allowed patent application is expected to expire no earlier than June 2035.  Full Article

MediciNova completes off-floor distribution
Tuesday, 17 May 2016 

MediciNova Inc : Says it completes the off-floor distribution of shares on May 17 .Says 800,000 shares of its common stock were sold at the price of 644 yen per share.  Full Article

MediciNova to offer off-floor distribution of 800,000 shares
Monday, 16 May 2016 

MediciNova Inc <4875.T>: Says it to offer an off-floor distribution of 800,000 shares of its stock at the price of 644 yen per share, on the Tokyo Stock Exchange on May 17 .Says the limitation for purchase of the distribution is up to 10,000 shares for each customer.  Full Article

MediciNova to offer off-floor distribution of shares
Tuesday, 10 May 2016 

MediciNova Inc : Says it to offer an off-floor distribution of 800,000 shares on Tokyo Stock Exchange between May 17 and May 19 . Says offering price will be determined based on the closing share price of the day before the distribution .Says the limitation for distribution is up to 1,000 shares for each customer.  Full Article

BRIEF-MediciNova Posts Results Of Phase 2 Clinical Trial Of MN-166 In Methamphetamine Dependence

* MEDICINOVA ANNOUNCES RESULTS OF PHASE 2 CLINICAL TRIAL OF MN-166 (IBUDILAST) IN METHAMPHETAMINE DEPENDENCE